Loading...

PHAT PHATHOM PHARMACEUTICALS INC Earnings Reports 8-K Filing

PHTH

PHT

PHATHOM PHARMACEUTICALS INC

(PHAT)

2023 8-K

Show Summary

Show Summary

Other Special Situation

Pre-Market Approval

Financial Statements

Director Appointment

Financial Results

Earnings Report

Financial Results

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

Other Special Situation

Bylaws Amendment

Loan Agreement Amendment

FDA Acceptance of New Drug ...

Financial Results Announcement

FDA Approval for VOQUEZNA T...

FDA Stability Data Submission

Financial Results Announcement

Stock Option Exchange

Stock Option Exchange

FDA Acknowledges NDA Resubm...

Annual Meeting and Changes ...

Underwriting Agreement

Resubmission of New Drug Ap...

Financial Results Announcement

Regulatory Update

Financial Results Announcement

Positive Study Results for ...

External Links:

Phathom Pharmaceuticals provided a regulatory update on the resubmission of their NDA for erosive esophagitis and the post approval supplement for their H. pylori NDAs, anticipating a commercial launch in Q4 2023.

AI Assistant

PHATHOM PHARMACEUTICALS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.